ANX005
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Huntington Disease
Conditions
Huntington Disease
Trial Timeline
Aug 17, 2020 → Jan 28, 2022
NCT ID
NCT04514367About ANX005
ANX005 is a phase 2 stage product being developed by Annexon for Huntington Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT04514367. Target conditions include Huntington Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04691570 | Phase 2 | Completed |
| NCT04569435 | Phase 2 | Completed |
| NCT04514367 | Phase 2 | Completed |
Competing Products
20 competing products in Huntington Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| atomoxetine + Matching Placebo | Eli Lilly | Phase 2 | 52 |
| Votoplam (blinded) + Placebo | Novartis | Phase 3 | 77 |
| Votoplam | Novartis | Phase 2 | 52 |
| Branaplam + Placebo | Novartis | Phase 2 | 52 |
| AFQ056 + Placebo | Novartis | Phase 2 | 52 |
| RO7234292 (RG6042) | Roche | Phase 1 | 33 |
| Tominersen + Placebo | Roche | Phase 2 | 52 |
| RO7234292 (RG6042) | Roche | Phase 3 | 77 |
| RO7234292 (RG6042) | Roche | Phase 2 | 52 |
| RG6496 + Placebo | Roche | Phase 1 | 33 |
| RO7234292 + Placebo | Roche | Phase 3 | 77 |
| PF-02545920 + PF-02545920 | Pfizer | Phase 2 | 51 |
| Dextromethorphan + Dimebon + Dextromethorphan | Pfizer | Phase 1 | 32 |
| Dimebon | Pfizer | Phase 3 | 76 |
| Dimebon (latrepirdine) | Pfizer | Phase 3 | 76 |
| 20 mg BID of PF-02545920 | Pfizer | Phase 2 | 51 |
| PF-02545920 + Placebo + PF-02545920 + Placebo | Pfizer | Phase 2 | 51 |
| Riluzole | Sanofi | Phase 3 | 76 |
| ALN-HTT02 + Placebo | Alnylam Pharmaceuticals | Phase 1 | 30 |
| Tetrabenazine | Lundbeck | Approved | 82 |